{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:01:25Z","timestamp":1790348485699,"version":"4.1.0"},"reference-count":133,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,5]]},"DOI":"10.7759\/cureus.19274","type":"journal-article","created":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T10:35:27Z","timestamp":1636108527000},"source":"Crossref","is-referenced-by-count":62,"title":["Hepatocellular Carcinoma in 2021: An Exhaustive Update"],"prefix":"10.7759","author":[{"given":"Cyriac A","family":"Philips","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasidharan","family":"Rajesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinu C","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizwan","family":"Ahamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsha K","family":"Abduljaleel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Augustine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner A","year":"2018","unstructured":"Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018, 391:1301-14. 10.1016\/S0140-6736(18)30010-2","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2017.08.010","article-title":"Hepatocellular carcinoma: present and future","volume":"150","author":"Armengol C","year":"2018","unstructured":"Armengol C, Sarrias MR, Sala M. Hepatocellular carcinoma: present and future. Med Clin (Barc). 2018, 150:390-7. 10.1016\/j.medcli.2017.08.010","journal-title":"Med Clin (Barc)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2016.12.011","article-title":"The diagnosis and treatment of hepatocellular carcinoma","volume":"34","author":"Hartke J","year":"2017","unstructured":"Hartke J, Johnson M, Ghabril M. The diagnosis and treatment of hepatocellular carcinoma. Semin Diagn Pathol. 2017, 34:153-9. 10.1053\/j.semdp.2016.12.011","journal-title":"Semin Diagn Pathol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i29.5282","article-title":"From diagnosis to treatment of hepatocellular carcinoma: an epidemic problem for both developed and developing world","volume":"23","author":"Dimitroulis D","year":"2017","unstructured":"Dimitroulis D, Damaskos C, Valsami S, et al.. From diagnosis to treatment of hepatocellular carcinoma: an epidemic problem for both developed and developing world. World J Gastroenterol. 2017, 23:5282-94. 10.3748\/wjg.v23.i29.5282","journal-title":"World J Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3055","article-title":"The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level. Results from the Global Burden of Disease Study 2015","volume":"3","author":"Akinyemiju T","year":"2017","unstructured":"Akinyemiju T, Abera S, Ahmed M, et al.. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level. Results from the Global Burden of Disease Study 2015. JAMA Oncol. 2017, 3:1683-91. 10.1001\/jamaoncol.2017.3055","journal-title":"JAMA Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29498","article-title":"Projections of primary liver cancer to 2030 in 30 countries worldwide","volume":"67","author":"Valery PC","year":"2018","unstructured":"Valery PC, Laversanne M, Clark PJ, Petrick JL, McGlynn KA, Bray F. Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology. 2018, 67:600-11. 10.1002\/hep.29498","journal-title":"Hepatology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.11.045","article-title":"Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis","volume":"58","author":"Lin CW","year":"2013","unstructured":"Lin CW, Lin CC, Mo LR, et al.. Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis. J Hepatol. 2013, 58:730-5. 10.1016\/j.jhep.2012.11.045","journal-title":"J Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(19)30488-7","article-title":"Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis","volume":"8","author":"de Martel C","year":"2020","unstructured":"de Martel C, Georges D, Bray F, et al.. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob Health. 2020, 8:180-90. 10.1016\/S2214-109X(19)30488-7","journal-title":"Lancet Glob Health"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2019.05.001","article-title":"The oncogenic role of hepatitis delta virus in hepatocellular carcinoma","volume":"1","author":"Puigveh\u00ed M","year":"2019","unstructured":"Puigveh\u00ed M, Moctezuma-Vel\u00e1zquez C, Villanueva A, Llovet JM. The oncogenic role of hepatitis delta virus in hepatocellular carcinoma. JHEP Rep. 2019, 1:120-30. 10.1016\/j.jhepr.2019.05.001","journal-title":"JHEP Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-313622","article-title":"High BMI in late adolescence predicts future severe liver disease and hepatocellular carcinoma: a national, population-based cohort study in 1.2 million men","volume":"67","author":"Hagstr\u00f6m H","year":"2018","unstructured":"Hagstr\u00f6m H, Tynelius P, Rasmussen F. High BMI in late adolescence predicts future severe liver disease and hepatocellular carcinoma: a national, population-based cohort study in 1.2 million men. Gut. 2018, 67:1536-42. 10.1136\/gutjnl-2016-313622","journal-title":"Gut"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30737","article-title":"Adiposity across the adult life course and incidence of primary liver cancer: the NIH-AARP cohort","volume":"141","author":"Yang B","year":"2017","unstructured":"Yang B, Petrick JL, Kelly SP, Graubard BI, Freedman ND, McGlynn KA. Adiposity across the adult life course and incidence of primary liver cancer: the NIH-AARP cohort. Int J Cancer. 2017, 141:271-8. 10.1002\/ijc.30737","journal-title":"Int J Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease","volume":"155","author":"Kanwal F","year":"2018","unstructured":"Kanwal F, Kramer JR, Mapakshi S, et al.. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology. 2018, 155:1828-1837.e2. 10.1053\/j.gastro.2018.08.024","journal-title":"Gastroenterology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-019-01345-y","article-title":"Epidemiological and etiological variations in hepatocellular carcinoma","volume":"48","author":"Sagnelli E","year":"2020","unstructured":"Sagnelli E, Macera M, Russo A, Coppola N, Sagnelli C. Epidemiological and etiological variations in hepatocellular carcinoma. Infection. 2020, 48:7-17. 10.1007\/s15010-019-01345-y","journal-title":"Infection"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of hepatocellular carcinoma","volume":"73 Suppl 1","author":"McGlynn KA","year":"2021","unstructured":"McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021, 73 Suppl 1:4-13. 10.1002\/hep.31288","journal-title":"Hepatology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/CEJ.0000000000000252","article-title":"Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies","volume":"26","author":"Bravi F","year":"2017","unstructured":"Bravi F, Tavani A, Bosetti C, Boffetta P, La Vecchia C. Coffee and the risk of hepatocellular carcinoma and chronic liver disease: a systematic review and meta-analysis of prospective studies. Eur J Cancer Prev. 2017, 26:368-77. 10.1097\/CEJ.0000000000000252","journal-title":"Eur J Cancer Prev"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13872","article-title":"Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes","volume":"38","author":"Tseng CH","year":"2018","unstructured":"Tseng CH. Metformin and risk of hepatocellular carcinoma in patients with type 2 diabetes. Liver Int. 2018, 38:2018-27. 10.1111\/liv.13872","journal-title":"Liver Int"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.4154","article-title":"Association between aspirin use and risk of hepatocellular carcinoma","volume":"4","author":"Simon TG","year":"2018","unstructured":"Simon TG, Ma Y, Ludvigsson JF, et al.. Association between aspirin use and risk of hepatocellular carcinoma. JAMA Oncol. 2018, 4:1683-90. 10.1001\/jamaoncol.2018.4154","journal-title":"JAMA Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32426","article-title":"Statin use and risk of liver cancer: evidence from two population-based studies","volume":"146","author":"Tran KT","year":"2020","unstructured":"Tran KT, McMenamin \u00daC, Coleman HG, et al.. Statin use and risk of liver cancer: evidence from two population-based studies. Int J Cancer. 2020, 146:1250-60. 10.1002\/ijc.32426","journal-title":"Int J Cancer"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.08.030","article-title":"HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma","volume":"68","author":"Ioannou GN","year":"2017","unstructured":"Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol. 2017, 68:25-32. 10.1016\/j.jhep.2017.08.030","journal-title":"J Hepatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29855","article-title":"Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout","volume":"68","author":"Huang AC","year":"2018","unstructured":"Huang AC, Mehta N, Dodge JL, Yao FY, Terrault NA. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout. Hepatology. 2018, 68:449-61. 10.1002\/hep.29855","journal-title":"Hepatology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308786","article-title":"Association between ultrasonography screening and mortality in patients with hepatocellular carcinoma: a nationwide cohort study","volume":"65","author":"Wu CY","year":"2016","unstructured":"Wu CY, Hsu YC, Ho HJ, Chen YJ, Lee TY, Lin JT. Association between ultrasonography screening and mortality in patients with hepatocellular carcinoma: a nationwide cohort study. Gut. 2016, 65:693-701. 10.1136\/gutjnl-2014-308786","journal-title":"Gut"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.3147","article-title":"MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma","volume":"3","author":"Kim SY","year":"2017","unstructured":"Kim SY, An J, Lim YS, et al.. MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncol. 2017, 3:456-63. 10.1001\/jamaoncol.2016.3147","journal-title":"JAMA Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.01.041","article-title":"Abbreviated MRI for hepatocellular carcinoma screening: a systematic review and meta-analysis","volume":"75","author":"Gupta P","year":"2021","unstructured":"Gupta P, Soundararajan R, Patel A, Kumar-M P, Sharma V, Kalra N. Abbreviated MRI for hepatocellular carcinoma screening: a systematic review and meta-analysis. J Hepatol. 2021, 75:108-19. 10.1016\/j.jhep.2021.01.041","journal-title":"J Hepatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.08.025","article-title":"Epidemiology and surveillance for hepatocellular carcinoma: new trends","volume":"72","author":"Singal AG","year":"2020","unstructured":"Singal AG, Lampertico P, Nahon P. Epidemiology and surveillance for hepatocellular carcinoma: new trends. J Hepatol. 2020, 72:250-61. 10.1016\/j.jhep.2019.08.025","journal-title":"J Hepatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-18-0281","article-title":"GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score","volume":"28","author":"Yang JD","year":"2019","unstructured":"Yang JD, Addissie BD, Mara KC, et al.. GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score. Cancer Epidemiol Biomarkers Prev. 2019, 28:531-8. 10.1158\/1055-9965.EPI-18-0281","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071681","article-title":"Serum biomarkers for the prediction of hepatocellular carcinoma","volume":"13","author":"Debes JD","year":"2021","unstructured":"Debes JD, Romagnoli PA, Prieto J, et al.. Serum biomarkers for the prediction of hepatocellular carcinoma. Cancers (Basel). 2021, 13:1681. 10.3390\/cancers13071681","journal-title":"Cancers (Basel)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30244","article-title":"Hepatocellular carcinoma detection by plasma methylated DNA: discovery, phase I pilot, and phase II clinical validation","volume":"69","author":"Kisiel JB","year":"2019","unstructured":"Kisiel JB, Dukek BA, V S R Kanipakam R, et al.. Hepatocellular carcinoma detection by plasma methylated DNA: discovery, phase I pilot, and phase II clinical validation. Hepatology. 2019, 69:1180-92. 10.1002\/hep.30244","journal-title":"Hepatology"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30818","article-title":"The association between individual metabolic syndrome components, primary liver cancer and cirrhosis: a study in the Swedish AMORIS cohort","volume":"141","author":"Nderitu P","year":"2017","unstructured":"Nderitu P, Bosco C, Garmo H, et al.. The association between individual metabolic syndrome components, primary liver cancer and cirrhosis: a study in the Swedish AMORIS cohort. Int J Cancer. 2017, 141:1148-60. 10.1002\/ijc.30818","journal-title":"Int J Cancer"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-61028-9","article-title":"Evolution of etiology, presentation, management and prognostic tool in hepatocellular carcinoma","volume":"10","author":"Ho SY","year":"2020","unstructured":"Ho SY, Liu PH, Hsu CY, et al.. Evolution of etiology, presentation, management and prognostic tool in hepatocellular carcinoma. Sci Rep. 2020, 10:3925. 10.1038\/s41598-020-61028-9","journal-title":"Sci Rep"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000068","article-title":"Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study","volume":"114","author":"Feng Z","year":"2019","unstructured":"Feng Z, Marrero JA, Khaderi S, et al.. Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study. Am J Gastroenterol. 2019, 114:530-2. 10.14309\/ajg.0000000000000068","journal-title":"Am J Gastroenterol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.11.006","article-title":"Milestones in the pathogenesis and management of primary liver cancer","volume":"72","author":"Nault JC","year":"2020","unstructured":"Nault JC, Cheng AL, Sangro B, Llovet JM. Milestones in the pathogenesis and management of primary liver cancer. J Hepatol. 2020, 72:209-14. 10.1016\/j.jhep.2019.11.006","journal-title":"J Hepatol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0519-y","article-title":"Necroptosis microenvironment directs lineage commitment in liver cancer","volume":"562","author":"Seehawer M","year":"2018","unstructured":"Seehawer M, Heinzmann F, D'Artista L, et al.. Necroptosis microenvironment directs lineage commitment in liver cancer. Nature. 2018, 562:69-75. 10.1038\/s41586-018-0519-y","journal-title":"Nature"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.11.048","article-title":"Liver cancer cell of origin, molecular class, and effects on patient prognosis","volume":"152","author":"Sia D","year":"2017","unstructured":"Sia D, Villanueva A, Friedman SL, Llovet JM. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. 2017, 152:745-61. 10.1053\/j.gastro.2016.11.048","journal-title":"Gastroenterology"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3252","article-title":"Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets","volume":"47","author":"Schulze K","year":"2015","unstructured":"Schulze K, Imbeaud S, Letouz\u00e9 E, et al.. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015, 47:505-11. 10.1038\/ng.3252","journal-title":"Nat Genet"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3126","article-title":"Trans-ancestry mutational landscape of hepatocellular carcinoma genomes","volume":"46","author":"Totoki Y","year":"2014","unstructured":"Totoki Y, Tatsuno K, Covington KR, et al.. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet. 2014, 46:1267-73. 10.1038\/ng.3126","journal-title":"Nat Genet"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.08.017","article-title":"Advances in molecular classification and precision oncology in hepatocellular carcinoma","volume":"72","author":"Rebouissou S","year":"2020","unstructured":"Rebouissou S, Nault JC. Advances in molecular classification and precision oncology in hepatocellular carcinoma. J Hepatol. 2020, 72:215-29. 10.1016\/j.jhep.2019.08.017","journal-title":"J Hepatol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.02.035","article-title":"Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis","volume":"57","author":"Nahon P","year":"2012","unstructured":"Nahon P, Zucman-Rossi J. Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis. J Hepatol. 2012, 57:663-74. 10.1016\/j.jhep.2012.02.035","journal-title":"J Hepatol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0041-8","article-title":"Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis","volume":"113","author":"Stickel F","year":"2018","unstructured":"Stickel F, Buch S, Nischalke HD, et al.. Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis. Am J Gastroenterol. 2018, 113:1475-83. 10.1038\/s41395-018-0041-8","journal-title":"Am J Gastroenterol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2016.05.027","article-title":"Mutational signature of aristolochic acid: clue to the recognition of a global disease","volume":"44","author":"Rosenquist TA","year":"2016","unstructured":"Rosenquist TA, Grollman AP. Mutational signature of aristolochic acid: clue to the recognition of a global disease. DNA Repair (Amst). 2016, 44:205-11. 10.1016\/j.dnarep.2016.05.027","journal-title":"DNA Repair (Amst)"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07552-9","article-title":"Cyclin A2\/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress","volume":"9","author":"Bayard Q","year":"2018","unstructured":"Bayard Q, Meunier L, Peneau C, et al.. Cyclin A2\/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress. Nat Commun. 2018, 9:5235. 10.1038\/s41467-018-07552-9","journal-title":"Nat Commun"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.10.033","article-title":"Mechanisms of HBV-related hepatocarcinogenesis","volume":"52","author":"Neuveut C","year":"2010","unstructured":"Neuveut C, Wei Y, Buendia MA. Mechanisms of HBV-related hepatocarcinogenesis. J Hepatol. 2010, 52:594-604. 10.1016\/j.jhep.2009.10.033","journal-title":"J Hepatol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3389","article-title":"Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas","volume":"47","author":"Nault JC","year":"2015","unstructured":"Nault JC, Datta S, Imbeaud S, et al.. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat Genet. 2015, 47:1187-93. 10.1038\/ng.3389","journal-title":"Nat Genet"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.08.016","article-title":"Gut microbiome in HCC - mechanisms, diagnosis and therapy","volume":"72","author":"Schwabe RF","year":"2020","unstructured":"Schwabe RF, Greten TF. Gut microbiome in HCC - mechanisms, diagnosis and therapy. J Hepatol. 2020, 72:230-8. 10.1016\/j.jhep.2019.08.016","journal-title":"J Hepatol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2016.01.077","article-title":"Profile of gut microbiota associated with the presence of hepatocellular cancer in patients with liver cirrhosis","volume":"48","author":"Gr\u0105t M","year":"2016","unstructured":"Gr\u0105t M, Wronka KM, Krasnod\u0119bski M, et al.. Profile of gut microbiota associated with the presence of hepatocellular cancer in patients with liver cirrhosis. Transplant Proc. 2016, 48:1687-91. 10.1016\/j.transproceed.2016.01.077","journal-title":"Transplant Proc"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2017-315084","article-title":"Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma","volume":"68","author":"Ren Z","year":"2019","unstructured":"Ren Z, Li A, Jiang J, et al.. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut. 2019, 68:1014-23. 10.1136\/gutjnl-2017-315084","journal-title":"Gut"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.09.004","article-title":"Dysregulated microbial fermentation of soluble fiber induces cholestatic liver cancer","volume":"175","author":"Singh V","year":"2018","unstructured":"Singh V, Yeoh BS, Chassaing B, et al.. Dysregulated microbial fermentation of soluble fiber induces cholestatic liver cancer. Cell. 2018, 175:679-694.e22. 10.1016\/j.cell.2018.09.004","journal-title":"Cell"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30036","article-title":"Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease","volume":"69","author":"Ponziani FR","year":"2019","unstructured":"Ponziani FR, Bhoori S, Castelli C, et al.. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology. 2019, 69:107-20. 10.1002\/hep.30036","journal-title":"Hepatology"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1186\/s13099-018-0281-6","article-title":"Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus related hepatocellular carcinoma","volume":"11","author":"Liu Q","year":"2019","unstructured":"Liu Q, Li F, Zhuang Y, et al.. Alteration in gut microbiota associated with hepatitis B and non-hepatitis virus related hepatocellular carcinoma. Gut Pathog. 2019, 11:1. 10.1186\/s13099-018-0281-6","journal-title":"Gut Pathog"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.01.064","article-title":"Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis","volume":"154","author":"Tzartzeva K","year":"2018","unstructured":"Tzartzeva K, Obi J, Rich NE, et al.. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018, 154:1706-1718.e1. 10.1053\/j.gastro.2018.01.064","journal-title":"Gastroenterology"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.12.005","article-title":"Validation of the hepatocellular carcinoma early detection screening (HES) algorithm in a cohort of veterans with cirrhosis","volume":"17","author":"Tayob N","year":"2019","unstructured":"Tayob N, Christie I, Richardson P, et al.. Validation of the hepatocellular carcinoma early detection screening (HES) algorithm in a cohort of veterans with cirrhosis. Clin Gastroenterol Hepatol. 2019, 17:1886-1893.e5. 10.1016\/j.cgh.2018.12.005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30233","article-title":"Longitudinal assessment of three serum biomarkers to detect very early-stage hepatocellular carcinoma","volume":"69","author":"Choi J","year":"2019","unstructured":"Choi J, Kim GA, Han S, Lee W, Chun S, Lim YS. Longitudinal assessment of three serum biomarkers to detect very early-stage hepatocellular carcinoma. Hepatology. 2019, 69:1983-94. 10.1002\/hep.30233","journal-title":"Hepatology"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.23262","article-title":"Clinical role of combining alpha-fetoprotein and lens culinaris agglutinin-reactive fraction of alpha-fetoprotein for hepatocellular carcinoma: evidence from literature and an original study","volume":"34","author":"Chen S","year":"2020","unstructured":"Chen S, Li J, Tan X, et al.. Clinical role of combining alpha-fetoprotein and lens culinaris agglutinin-reactive fraction of alpha-fetoprotein for hepatocellular carcinoma: evidence from literature and an original study. J Clin Lab Anal. 2020, 34:e23262. 10.1002\/jcla.23262","journal-title":"J Clin Lab Anal"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2014.06.008","article-title":"Comparison osteopontin vs AFP for the diagnosis of HCC: a meta-analysis","volume":"38","author":"Wan HG","year":"2014","unstructured":"Wan HG, Xu H, Gu YM, Wang H, Xu W, Zu MH. Comparison osteopontin vs AFP for the diagnosis of HCC: a meta-analysis. Clin Res Hepatol Gastroenterol. 2014, 38:706-14. 10.1016\/j.clinre.2014.06.008","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155800","article-title":"Midkine increases diagnostic yield in AFP negative and NASH-related hepatocellular carcinoma","volume":"11","author":"Vongsuvanh R","year":"2016","unstructured":"Vongsuvanh R, van der Poorten D, Iseli T, Strasser SI, McCaughan GW, George J. Midkine increases diagnostic yield in AFP negative and NASH-related hepatocellular carcinoma. PLoS One. 2016, 11:e0155800. 10.1371\/journal.pone.0155800","journal-title":"PLoS One"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151069","article-title":"Diagnostic performance of alpha-fetoprotein, protein induced by vitamin K absence, osteopontin, Dickkopf-1 and its combinations for hepatocellular carcinoma","volume":"11","author":"Jang ES","year":"2016","unstructured":"Jang ES, Jeong SH, Kim JW, Choi YS, Leissner P, Brechot C. Diagnostic performance of alpha-fetoprotein, protein induced by vitamin K absence, osteopontin, Dickkopf-1 and its combinations for hepatocellular carcinoma. PLoS One. 2016, 11:e0151069. 10.1371\/journal.pone.0151069","journal-title":"PLoS One"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-20-0005","article-title":"Biomarkers for the early detection of hepatocellular carcinoma","volume":"29","author":"Parikh ND","year":"2020","unstructured":"Parikh ND, Mehta AS, Singal AG, Block T, Marrero JA, Lok AS. Biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev. 2020, 29:2495-503. 10.1158\/1055-9965.EPI-20-0005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2017.09.007","article-title":"Plasma heat shock protein 90alpha as a biomarker for the diagnosis of liver cancer: an official, large-scale, and multicenter clinical trial","volume":"24","author":"Fu Y","year":"2017","unstructured":"Fu Y, Xu X, Huang D, et al.. Plasma heat shock protein 90alpha as a biomarker for the diagnosis of liver cancer: an official, large-scale, and multicenter clinical trial. EBioMedicine. 2017, 24:56-63. 10.1016\/j.ebiom.2017.09.007","journal-title":"EBioMedicine"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S217170","article-title":"Diagnostic value of angiopoietin-like protein 2 for CHB-related hepatocellular carcinoma","volume":"11","author":"Zhou J","year":"2019","unstructured":"Zhou J, Yang W, Zhang S, et al.. Diagnostic value of angiopoietin-like protein 2 for CHB-related hepatocellular carcinoma. Cancer Manag Res. 2019, 11:7159-69. 10.2147\/CMAR.S217170","journal-title":"Cancer Manag Res"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2019.749","article-title":"Soluble Axl is a novel diagnostic biomarker of hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection","volume":"52","author":"Song X","year":"2020","unstructured":"Song X, Wu A, Ding Z, Liang S, Zhang C. Soluble Axl is a novel diagnostic biomarker of hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. Cancer Res Treat. 2020, 52:789-97. 10.4143\/crt.2019.749","journal-title":"Cancer Res Treat"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2017.5890","article-title":"Assessment of high-sensitivity C-reactive protein tests for the diagnosis of hepatocellular carcinoma in patients with hepatitis B-associated liver cirrhosis","volume":"13","author":"Ma LN","year":"2017","unstructured":"Ma LN, Liu XY, Lu ZH, et al.. Assessment of high-sensitivity C-reactive protein tests for the diagnosis of hepatocellular carcinoma in patients with hepatitis B-associated liver cirrhosis. Oncol Lett. 2017, 13:3457-64. 10.3892\/ol.2017.5890","journal-title":"Oncol Lett"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-020-02390-y","article-title":"Establishing peripheral PD-L1 as a prognostic marker in hepatocellular carcinoma patients: how long will it come true?","volume":"23","author":"Sun DW","year":"2021","unstructured":"Sun DW, An L, Huang HY, Sun XD, Lv GY. Establishing peripheral PD-L1 as a prognostic marker in hepatocellular carcinoma patients: how long will it come true?. Clin Transl Oncol. 2021, 23:82-91. 10.1007\/s12094-020-02390-y","journal-title":"Clin Transl Oncol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v12.i9.558","article-title":"Biomarkers for hepatocellular cancer","volume":"12","author":"Singh G","year":"2020","unstructured":"Singh G, Yoshida EM, Rathi S, Marquez V, Kim P, Erb SR, Salh BS. Biomarkers for hepatocellular cancer. World J Hepatol. 2020, 12:558-73. 10.4254\/wjh.v12.i9.558","journal-title":"World J Hepatol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-020-10130-1","article-title":"S100P as a novel biomarker of microvascular invasion and portal vein tumor thrombus in hepatocellular carcinoma","volume":"15","author":"Qi LN","year":"2021","unstructured":"Qi LN, Ma L, Wu FX, et al.. S100P as a novel biomarker of microvascular invasion and portal vein tumor thrombus in hepatocellular carcinoma. Hepatol Int. 2021, 15:114-26. 10.1007\/s12072-020-10130-1","journal-title":"Hepatol Int"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.344","article-title":"In-depth proteomic analysis of tissue interstitial fluid for hepatocellular carcinoma serum biomarker discovery","volume":"117","author":"Zhang J","year":"2017","unstructured":"Zhang J, Hao N, Liu W, et al.. In-depth proteomic analysis of tissue interstitial fluid for hepatocellular carcinoma serum biomarker discovery. Br J Cancer. 2017, 117:1676-84. 10.1038\/bjc.2017.344","journal-title":"Br J Cancer"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29561","article-title":"A large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma","volume":"67","author":"Luo P","year":"2018","unstructured":"Luo P, Yin P, Hua R, et al.. A large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma. Hepatology. 2018, 67:662-75. 10.1002\/hep.29561","journal-title":"Hepatology"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.0c04259","article-title":"LC\/MS-based global metabolomic identification of serum biomarkers differentiating hepatocellular carcinoma from chronic hepatitis B and liver cirrhosis","volume":"6","author":"Pan HY","year":"2021","unstructured":"Pan HY, Wu QQ, Yin QQ, et al.. LC\/MS-based global metabolomic identification of serum biomarkers differentiating hepatocellular carcinoma from chronic hepatitis B and liver cirrhosis. ACS Omega. 2021, 6:1160-70. 10.1021\/acsomega.0c04259","journal-title":"ACS Omega"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01316","article-title":"New blood biomarkers for the diagnosis of AFP-negative hepatocellular carcinoma","volume":"10","author":"Wang T","year":"2020","unstructured":"Wang T, Zhang KH. New blood biomarkers for the diagnosis of AFP-negative hepatocellular carcinoma. Front Oncol. 2020, 10:1316. 10.3389\/fonc.2020.01316","journal-title":"Front Oncol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1565","article-title":"A distinctively expressed long noncoding RNA, RP11-466I1.1, may serve as a prognostic biomarker in hepatocellular carcinoma","volume":"7","author":"Zhang J","year":"2018","unstructured":"Zhang J, Zhang D, Zhao Q, Qi J, Li X, Qin C. A distinctively expressed long noncoding RNA, RP11-466I1.1, may serve as a prognostic biomarker in hepatocellular carcinoma. Cancer Med. 2018, 7:2960-8. 10.1002\/cam4.1565","journal-title":"Cancer Med"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007513","article-title":"The diagnostic value of assays for circulating tumor cells in hepatocellular carcinoma. A meta-analysis","volume":"96","author":"Sun C","year":"2017","unstructured":"Sun C, Liao W, Deng Z, et al.. The diagnostic value of assays for circulating tumor cells in hepatocellular carcinoma. A meta-analysis. Medicine (Baltimore). 2017, 96:e7513. 10.1097\/MD.0000000000007513","journal-title":"Medicine (Baltimore)"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25476","article-title":"Genetic variations in death receptor domain 4 gene and the susceptibility to hepatitis C related hepatocellular carcinoma","volume":"91","author":"Zayed SA","year":"2019","unstructured":"Zayed SA, Zahran NM, Khorshied MM, et al.. Genetic variations in death receptor domain 4 gene and the susceptibility to hepatitis C related hepatocellular carcinoma. J Med Virol. 2019, 91:1537-44. 10.1002\/jmv.25476","journal-title":"J Med Virol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.01.041","article-title":"Genome-wide association study identifies TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus infection","volume":"152","author":"Matsuura K","year":"2017","unstructured":"Matsuura K, Sawai H, Ikeo K, et al.. Genome-wide association study identifies TLL1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus infection. Gastroenterology. 2017, 152:1383-94. 10.1053\/j.gastro.2017.01.041","journal-title":"Gastroenterology"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20181400","article-title":"SNP rs2596542G>A in MICA is associated with risk of hepatocellular carcinoma: a meta-analysis","volume":"39","author":"Wang H","year":"2019","unstructured":"Wang H, Cao H, Xu Z, Wang D, Zeng Y. SNP rs2596542G>A in MICA is associated with risk of hepatocellular carcinoma: a meta-analysis. Biosci Rep. 2019, 39:BSR20181400. 10.1042\/BSR20181400","journal-title":"Biosci Rep"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1038\/srep33142","article-title":"Deep sequencing reveals microbiota dysbiosis of tongue coat in patients with liver carcinoma","volume":"6","author":"Lu H","year":"2016","unstructured":"Lu H, Ren Z, Li A, et al.. Deep sequencing reveals microbiota dysbiosis of tongue coat in patients with liver carcinoma. Sci Rep. 2016, 6:33142. 10.1038\/srep33142","journal-title":"Sci Rep"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2015.12.042","article-title":"Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients","volume":"14","author":"Berhane S","year":"2016","unstructured":"Berhane S, Toyoda H, Tada T, et al.. Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. Clin Gastroenterol Hepatol. 2016, 14:875-886.e6. 10.1016\/j.cgh.2015.12.042","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.11.012","article-title":"GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis","volume":"18","author":"Best J","year":"2020","unstructured":"Best J, Bechmann LP, Sowa JP, et al.. GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2020, 18:728-735.e4. 10.1016\/j.cgh.2019.11.012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-16-0974","article-title":"Changes in the glycosylation of kininogen and the development of a kininogen-based algorithm for the early detection of HCC","volume":"26","author":"Wang M","year":"2017","unstructured":"Wang M, Sanda M, Comunale MA, et al.. Changes in the glycosylation of kininogen and the development of a kininogen-based algorithm for the early detection of HCC. Cancer Epidemiol Biomarkers Prev. 2017, 26:795-803. 10.1158\/1055-9965.EPI-16-0974","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.15626","article-title":"Assessment of a deep learning model to predict hepatocellular carcinoma in patients with hepatitis C cirrhosis","volume":"3","author":"Ioannou GN","year":"2020","unstructured":"Ioannou GN, Tang W, Beste LA, et al.. Assessment of a deep learning model to predict hepatocellular carcinoma in patients with hepatitis C cirrhosis. JAMA Netw Open. 2020, 3:e2015626. 10.1001\/jamanetworkopen.2020.15626","journal-title":"JAMA Netw Open"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2020.00254","article-title":"Early diagnosis of hepatocellular carcinoma using machine learning method","volume":"8","author":"Zhang ZM","year":"2020","unstructured":"Zhang ZM, Tan JX, Wang F, Dao FY, Zhang ZY, Lin H. Early diagnosis of hepatocellular carcinoma using machine learning method. Front Bioeng Biotechnol. 2020, 8:254. 10.3389\/fbioe.2020.00254","journal-title":"Front Bioeng Biotechnol"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-320930","article-title":"Exploring prognostic indicators in the pathological images of hepatocellular carcinoma based on deep learning","volume":"70","author":"Shi JY","year":"2021","unstructured":"Shi JY, Wang X, Ding GY, et al.. Exploring prognostic indicators in the pathological images of hepatocellular carcinoma based on deep learning. Gut. 2021, 70:951-61. 10.1136\/gutjnl-2020-320930","journal-title":"Gut"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-019-06458-4","article-title":"Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid","volume":"30","author":"Semaan S","year":"2020","unstructured":"Semaan S, Vietti Violi N, Lewis S, et al.. Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid. Eur Radiol. 2020, 30:1020-30. 10.1007\/s00330-019-06458-4","journal-title":"Eur Radiol"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.2478\/raon-2021-0004","article-title":"An overview of hepatocellular carcinoma with atypical enhancement pattern: spectrum of magnetic resonance imaging findings with pathologic correlation","volume":"55","author":"Kovac JD","year":"2021","unstructured":"Kovac JD, Ivanovic A, Milovanovic T, Micev M, Alessandrino F, Gore RM. An overview of hepatocellular carcinoma with atypical enhancement pattern: spectrum of magnetic resonance imaging findings with pathologic correlation. Radiol Oncol. 2021, 55:130-43. 10.2478\/raon-2021-0004","journal-title":"Radiol Oncol"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.26797","article-title":"MRI-based risk factors of hepatocellular carcinoma in patients with chronic liver disease: a prospective observational study","volume":"51","author":"Shimizu T","year":"2020","unstructured":"Shimizu T, Motosugi U, Komatsu N, Ichikawa S, Inoue T, Onishi H, Enomoto N. MRI-based risk factors of hepatocellular carcinoma in patients with chronic liver disease: a prospective observational study. J Magn Reson Imaging. 2020, 51:389-96. 10.1002\/jmri.26797","journal-title":"J Magn Reson Imaging"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S113909","article-title":"Intravoxel incoherent motion model-based analysis of diffusion-weighted magnetic resonance imaging with 3 b-values for response assessment in locoregional therapy of hepatocellular carcinoma","volume":"9","author":"M\u00fcrtz P","year":"2016","unstructured":"M\u00fcrtz P, Penner AH, Pfeiffer AK, et al.. Intravoxel incoherent motion model-based analysis of diffusion-weighted magnetic resonance imaging with 3 b-values for response assessment in locoregional therapy of hepatocellular carcinoma. Onco Targets Ther. 2016, 9:6425-33. 10.2147\/OTT.S113909","journal-title":"Onco Targets Ther"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1186\/s13244-019-0690-1","article-title":"MRI assessment of hepatocellular carcinoma after locoregional therapy","volume":"10","author":"Hussein RS","year":"2019","unstructured":"Hussein RS, Tantawy W, Abbas YA. MRI assessment of hepatocellular carcinoma after locoregional therapy. Insights Imaging. 2019, 10:8. 10.1186\/s13244-019-0690-1","journal-title":"Insights Imaging"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-019-01997-2","article-title":"Value of 18F-FDG PET\/CT in the diagnosis of portal vein tumor thrombus in patients with hepatocellular carcinoma","volume":"44","author":"Wu B","year":"2019","unstructured":"Wu B, Zhang Y, Tan H, Shi H. Value of 18F-FDG PET\/CT in the diagnosis of portal vein tumor thrombus in patients with hepatocellular carcinoma. Abdom Radiol (NY). 2019, 44:2430-5. 10.1007\/s00261-019-01997-2","journal-title":"Abdom Radiol (NY)"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.02.023","article-title":"Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma","volume":"70","author":"Xu X","year":"2019","unstructured":"Xu X, Zhang HL, Liu QP, et al.. Radiomic analysis of contrast-enhanced CT predicts microvascular invasion and outcome in hepatocellular carcinoma. J Hepatol. 2019, 70:1133-44. 10.1016\/j.jhep.2019.02.023","journal-title":"J Hepatol"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.5152\/dir.2020.19569","article-title":"Hepatocellular carcinoma with macrovascular invasion: multimodality imaging features for the diagnosis","volume":"26","author":"Cannella R","year":"2020","unstructured":"Cannella R, Taibbi A, Porrello G, Dioguardi Burgio M, Cabibbo G, Bartolotta TV. Hepatocellular carcinoma with macrovascular invasion: multimodality imaging features for the diagnosis. Diagn Interv Radiol. 2020, 26:531-40. 10.5152\/dir.2020.19569","journal-title":"Diagn Interv Radiol"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.20517\/2394-5079.2018.40","article-title":"Staging of hepatocellular carcinoma","volume":"4","author":"Karademir S","year":"2018","unstructured":"Karademir S. Staging of hepatocellular carcinoma. Hepatoma Res. 2018, 4:58. 10.20517\/2394-5079.2018.40","journal-title":"Hepatoma Res"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.10.004","article-title":"Percutaneous treatment of hepatocellular carcinoma: state of the art and innovations","volume":"68","author":"Nault JC","year":"2018","unstructured":"Nault JC, Sutter O, Nahon P, Ganne-Carri\u00e9 N, S\u00e9ror O. Percutaneous treatment of hepatocellular carcinoma: state of the art and innovations. J Hepatol. 2018, 68:783-97. 10.1016\/j.jhep.2017.10.004","journal-title":"J Hepatol"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2018.1562571","article-title":"Comparison of microwave ablation and radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"36","author":"Tan W","year":"2019","unstructured":"Tan W, Deng Q, Lin S, Wang Y, Xu G. Comparison of microwave ablation and radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis. Int J Hyperthermia. 2019, 36:264-72. 10.1080\/02656736.2018.1562571","journal-title":"Int J Hyperthermia"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S204340","article-title":"Microwave ablation compared with radiofrequency ablation for treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis","volume":"12","author":"Glassberg MB","year":"2019","unstructured":"Glassberg MB, Ghosh S, Clymer JW, et al.. Microwave ablation compared with radiofrequency ablation for treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis. Onco Targets Ther. 2019, 12:6407-38. 10.2147\/OTT.S204340","journal-title":"Onco Targets Ther"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-018-5617-6","article-title":"Percutaneous cryoablation for perivascular hepatocellular carcinoma: therapeutic efficacy and vascular complications","volume":"29","author":"Kim R","year":"2019","unstructured":"Kim R, Kang TW, Cha DI, et al.. Percutaneous cryoablation for perivascular hepatocellular carcinoma: therapeutic efficacy and vascular complications. Eur Radiol. 2019, 29:654-62. 10.1007\/s00330-018-5617-6","journal-title":"Eur Radiol"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2017161413","article-title":"Safety and efficacy of irreversible electroporation for the treatment of hepatocellular carcinoma not amenable to thermal ablation techniques: a retrospective single-center case series","volume":"284","author":"Sutter O","year":"2017","unstructured":"Sutter O, Calvo J, N'Kontchou G, et al.. Safety and efficacy of irreversible electroporation for the treatment of hepatocellular carcinoma not amenable to thermal ablation techniques: a retrospective single-center case series. Radiology. 2017, 284:877-86. 10.1148\/radiol.2017161413","journal-title":"Radiology"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2018.01.090","article-title":"Electrochemotherapy as treatment option for hepatocellular carcinoma, a prospective pilot study","volume":"44","author":"Djokic M","year":"2018","unstructured":"Djokic M, Cemazar M, Popovic P, et al.. Electrochemotherapy as treatment option for hepatocellular carcinoma, a prospective pilot study. Eur J Surg Oncol. 2018, 44:651-7. 10.1016\/j.ejso.2018.01.090","journal-title":"Eur J Surg Oncol"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28453","article-title":"Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data","volume":"64","author":"Lencioni R","year":"2016","unstructured":"Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology. 2016, 64:106-16. 10.1002\/hep.28453","journal-title":"Hepatology"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1719186","article-title":"Therapy of Intermediate-stage hepatocellular carcinoma: current evidence and clinical practice","volume":"37","author":"Chai NX","year":"2020","unstructured":"Chai NX, Chapiro J. Therapy of Intermediate-stage hepatocellular carcinoma: current evidence and clinical practice. Semin Intervent Radiol. 2020, 37:456-65. 10.1055\/s-0040-1719186","journal-title":"Semin Intervent Radiol"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.4018","article-title":"Outcomes of patients with hepatocellular carcinoma treated with transarterial chemoembolization (TACE): global OPTIMIS final analysis","volume":"36","author":"Peck-Radosavljevic M","year":"2018","unstructured":"Peck-Radosavljevic M, Kudo M, Raoul J-C, et al.. Outcomes of patients with hepatocellular carcinoma treated with transarterial chemoembolization (TACE): global OPTIMIS final analysis. J Clin Oncol. 2018, 36:4018-10. 10.1200\/JCO.2018.36.15_suppl.4018","journal-title":"J Clin Oncol"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.01.013","article-title":"Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: a multicentre observational study","volume":"70","author":"Wang Q","year":"2019","unstructured":"Wang Q, Xia D, Bai W, et al.. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: a multicentre observational study. J Hepatol. 2019, 70:893-903. 10.1016\/j.jhep.2019.01.013","journal-title":"J Hepatol"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.423","article-title":"Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion","volume":"116","author":"Waked I","year":"2017","unstructured":"Waked I, Berhane S, Toyoda H, et al.. Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. Br J Cancer. 2017, 116:448-54. 10.1038\/bjc.2016.423","journal-title":"Br J Cancer"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2016.01.147","article-title":"Outcomes of radioembolization in the treatment of hepatocellular carcinoma with portal vein invasion: resin versus glass microspheres","volume":"27","author":"Biederman DM","year":"2016","unstructured":"Biederman DM, Titano JJ, Tabori NE, et al.. Outcomes of radioembolization in the treatment of hepatocellular carcinoma with portal vein invasion: resin versus glass microspheres. J Vasc Interv Radiol. 2016, 27:812-821.e2. 10.1016\/j.jvir.2016.01.147","journal-title":"J Vasc Interv Radiol"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial","volume":"18","author":"Vilgrain V","year":"2017","unstructured":"Vilgrain V, Pereira H, Assenat E, et al.. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017, 18:1624-36. 10.1016\/S1470-2045(17)30683-6","journal-title":"Lancet Oncol"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.0892","article-title":"SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma","volume":"36","author":"Chow PK","year":"2018","unstructured":"Chow PK, Gandhi M, Tan SB, et al.. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018, 36:1913-21. 10.1200\/JCO.2017.76.0892","journal-title":"J Clin Oncol"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2019.12.004","article-title":"Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: meta-analyses and a systematic review","volume":"145","author":"Lee J","year":"2020","unstructured":"Lee J, Shin IS, Yoon WS, Koom WS, Rim CH. Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: meta-analyses and a systematic review. Radiother Oncol. 2020, 145:63-70. 10.1016\/j.radonc.2019.12.004","journal-title":"Radiother Oncol"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2019.05.004","article-title":"Radiotherapy for HCC: ready for prime time?","volume":"1","author":"Bang A","year":"2019","unstructured":"Bang A, Dawson LA. Radiotherapy for HCC: ready for prime time?. JHEP Rep. 2019, 1:131-7. 10.1016\/j.jhepr.2019.05.004","journal-title":"JHEP Rep"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.05.066","article-title":"Comparison of stereotactic body radiation therapy and transarterial chemoembolization for unresectable medium-sized hepatocellular carcinoma","volume":"105","author":"Shen PC","year":"2019","unstructured":"Shen PC, Chang WC, Lo CH, et al.. Comparison of stereotactic body radiation therapy and transarterial chemoembolization for unresectable medium-sized hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2019, 105:307-18. 10.1016\/j.ijrobp.2019.05.066","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.09.001","article-title":"Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma","volume":"100","author":"Sapir E","year":"2018","unstructured":"Sapir E, Tao Y, Schipper MJ, et al.. Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2018, 100:122-30. 10.1016\/j.ijrobp.2017.09.001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-019-03096-7","article-title":"Proton beam therapy for hepatocellular carcinoma associated with inferior vena cava tumor thrombus","volume":"146","author":"Sekino Y","year":"2020","unstructured":"Sekino Y, Okumura T, Fukumitsu N, et al.. Proton beam therapy for hepatocellular carcinoma associated with inferior vena cava tumor thrombus. J Cancer Res Clin Oncol. 2020, 146:711-20. 10.1007\/s00432-019-03096-7","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.09.026","article-title":"Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase III trial","volume":"74","author":"Kim TH","year":"2021","unstructured":"Kim TH, Koh YH, Kim BH, Kim MJ, Lee JH, Park B, Park JW. Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase III trial. J Hepatol. 2021, 74:603-12. 10.1016\/j.jhep.2020.09.026","journal-title":"J Hepatol"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13813","article-title":"Meta-analysis of transcatheter arterial chemoembolization plus radiofrequency ablation versus transcatheter arterial chemoembolization alone for hepatocellular carcinoma","volume":"8","author":"Yang DJ","year":"2017","unstructured":"Yang DJ, Luo KL, Liu H, et al.. Meta-analysis of transcatheter arterial chemoembolization plus radiofrequency ablation versus transcatheter arterial chemoembolization alone for hepatocellular carcinoma. Oncotarget. 2017, 8:2960-70. 10.18632\/oncotarget.13813","journal-title":"Oncotarget"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.2174\/0929867327666201013162144","article-title":"Research progresses of targeted therapy and immunotherapy for hepatocellular carcinoma","volume":"28","author":"Wang T","year":"2021","unstructured":"Wang T, Zhang Q, Wang N, Liu Z, Zhang B, Zhao Y. Research progresses of targeted therapy and immunotherapy for hepatocellular carcinoma. Curr Med Chem. 2021, 28:3107-46. 10.2174\/0929867327666201013162144","journal-title":"Curr Med Chem"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4930","article-title":"Systemic therapy and sequencing options in advanced hepatocellular carcinoma: a systematic review and network meta-analysis","volume":"6","author":"Sonbol MB","year":"2020","unstructured":"Sonbol MB, Riaz IB, Naqvi SA, et al.. Systemic therapy and sequencing options in advanced hepatocellular carcinoma: a systematic review and network meta-analysis. JAMA Oncol. 2020, 6:e204930. 10.1001\/jamaoncol.2020.4930","journal-title":"JAMA Oncol"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1159\/000507934","article-title":"A paradigm change in the treatment strategy for hepatocellular carcinoma","volume":"9","author":"Kudo M","year":"2020","unstructured":"Kudo M. A paradigm change in the treatment strategy for hepatocellular carcinoma. Liver Cancer. 2020, 9:367-77. 10.1159\/000507934","journal-title":"Liver Cancer"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.09.010","article-title":"Molecular therapies for HCC: looking outside the box","volume":"72","author":"Faivre S","year":"2020","unstructured":"Faivre S, Rimassa L, Finn RS. Molecular therapies for HCC: looking outside the box. J Hepatol. 2020, 72:342-52. 10.1016\/j.jhep.2019.09.010","journal-title":"J Hepatol"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00264-x","article-title":"Targeted therapy for hepatocellular carcinoma","volume":"5","author":"Huang A","year":"2020","unstructured":"Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020, 5:146. 10.1038\/s41392-020-00264-x","journal-title":"Signal Transduct Target Ther"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0184597","article-title":"Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: a network meta-analysis of randomized controlled trials","volume":"12","author":"Katsanos K","year":"2017","unstructured":"Katsanos K, Kitrou P, Spiliopoulos S, Maroulis I, Petsas T, Karnabatidis D. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: a network meta-analysis of randomized controlled trials. PLoS One. 2017, 12:e0184597. 10.1371\/journal.pone.0184597","journal-title":"PLoS One"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2020.02.001","article-title":"Expanding TACTICS trial into a different setting in hepatocellular carcinoma","volume":"19","author":"da Fonseca L","year":"2020","unstructured":"da Fonseca L, Carrilho FJ. Expanding TACTICS trial into a different setting in hepatocellular carcinoma. Ann Hepatol. 2020, 19:230-1. 10.1016\/j.aohep.2020.02.001","journal-title":"Ann Hepatol"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.2217\/hep-2020-0004","article-title":"Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies","volume":"7","author":"Roderburg C","year":"2020","unstructured":"Roderburg C, \u00d6zdirik B, Wree A, Demir M, Tacke F. Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies. Hepat Oncol. 2020, 7:HEP20. 10.2217\/hep-2020-0004","journal-title":"Hepat Oncol"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.09.023","article-title":"Role of locoregional therapies in the wake of systemic therapy","volume":"72","author":"Palmer DH","year":"2020","unstructured":"Palmer DH, Malagari K, Kulik LM. Role of locoregional therapies in the wake of systemic therapy. J Hepatol. 2020, 72:277-87. 10.1016\/j.jhep.2019.09.023","journal-title":"J Hepatol"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1719187","article-title":"Therapy in advanced hepatocellular carcinoma","volume":"37","author":"Javan H","year":"2020","unstructured":"Javan H, Dayyani F, Abi-Jaoudeh N. Therapy in advanced hepatocellular carcinoma. Semin Intervent Radiol. 2020, 37:466-74. 10.1055\/s-0040-1719187","journal-title":"Semin Intervent Radiol"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000002889","article-title":"Liver transplantation and hepatic resection can achieve cure for hepatocellular carcinoma","volume":"268","author":"Pinna AD","year":"2018","unstructured":"Pinna AD, Yang T, Mazzaferro V, et al.. Liver transplantation and hepatic resection can achieve cure for hepatocellular carcinoma. Ann Surg. 2018, 268:868-75. 10.1097\/SLA.0000000000002889","journal-title":"Ann Surg"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000003433","article-title":"ALPPS versus portal vein embolization for hepatitis-related hepatocellular carcinoma. A changing paradigm in modulation of future liver remnant before major hepatectomy","volume":"273","author":"Chan A","year":"2021","unstructured":"Chan A, Zhang WY, Chok K, et al.. ALPPS versus portal vein embolization for hepatitis-related hepatocellular carcinoma. A changing paradigm in modulation of future liver remnant before major hepatectomy. Ann Surg. 2021, 273:957-65. 10.1097\/SLA.0000000000003433","journal-title":"Ann Surg"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-017-4744-9","article-title":"Extended liver venous deprivation before major hepatectomy induces marked and very rapid increase in future liver remnant function","volume":"27","author":"Guiu B","year":"2017","unstructured":"Guiu B, Quenet F, Escal L, et al.. Extended liver venous deprivation before major hepatectomy induces marked and very rapid increase in future liver remnant function. Eur Radiol. 2017, 27:3343-52. 10.1007\/s00330-017-4744-9","journal-title":"Eur Radiol"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2018.12.615","article-title":"Radioembolization for infiltrative hepatocellular carcinoma: analysis of 183-patient cohort","volume":"30","author":"Gabr A","year":"2019","unstructured":"Gabr A, Riaz A, Mouli S, Desai K, Thornburg B, Salem R, Lewandowski R. Radioembolization for infiltrative hepatocellular carcinoma: analysis of 183-patient cohort. J Vasc Interv Radiol. 2019, 30:231-2. 10.1016\/j.jvir.2018.12.615","journal-title":"J Vasc Interv Radiol"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0190512","article-title":"Prognostic value of liver stiffness measurement for the liver-related surgical outcomes of patients under hepatic resection: a meta-analysis","volume":"13","author":"Huang Z","year":"2018","unstructured":"Huang Z, Huang J, Zhou T, Cao H, Tan B. Prognostic value of liver stiffness measurement for the liver-related surgical outcomes of patients under hepatic resection: a meta-analysis. PLoS One. 2018, 13:e0190512. 10.1371\/journal.pone.0190512","journal-title":"PLoS One"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0219219","article-title":"A novel model for predicting posthepatectomy liver failure in patients with hepatocellular carcinoma","volume":"14","author":"Peng W","year":"2019","unstructured":"Peng W, Li JW, Zhang XY, Li C, Wen TF, Yan LN, Yang JY. A novel model for predicting posthepatectomy liver failure in patients with hepatocellular carcinoma. PLoS One. 2019, 14:e0219219. 10.1371\/journal.pone.0219219","journal-title":"PLoS One"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000002213","article-title":"How has virtual hepatectomy changed the practice of liver surgery? Experience of 1194 virtual hepatectomy before liver resection and living donor liver transplantation","volume":"268","author":"Mise Y","year":"2018","unstructured":"Mise Y, Hasegawa K, Satou S, et al.. How has virtual hepatectomy changed the practice of liver surgery? Experience of 1194 virtual hepatectomy before liver resection and living donor liver transplantation. Ann Surg. 2018, 268:127-33. 10.1097\/SLA.0000000000002213","journal-title":"Ann Surg"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-7073-6","article-title":"Long-term implications of unplanned conversion during laparoscopic liver resection for hepatocellular carcinoma","volume":"26","author":"Stiles ZE","year":"2019","unstructured":"Stiles ZE, Glazer ES, Deneve JL, Shibata D, Behrman SW, Dickson PV. Long-term implications of unplanned conversion during laparoscopic liver resection for hepatocellular carcinoma. Ann Surg Oncol. 2019, 26:282-9. 10.1245\/s10434-018-7073-6","journal-title":"Ann Surg Oncol"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2019.03.360","article-title":"Feasibility and safety of liver transplantation or resection after transarterial radioembolization with Yttrium-90 for unresectable hepatocellular carcinoma","volume":"21","author":"Labgaa I","year":"2019","unstructured":"Labgaa I, Tabrizian P, Titano J, et al.. Feasibility and safety of liver transplantation or resection after transarterial radioembolization with Yttrium-90 for unresectable hepatocellular carcinoma. HPB (Oxford). 2019, 21:1497-504. 10.1016\/j.hpb.2019.03.360","journal-title":"HPB (Oxford)"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27787","article-title":"Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validation","volume":"62","author":"Toso C","year":"2015","unstructured":"Toso C, Meeberg G, Hernandez-Alejandro R, Dufour JF, Marotta P, Majno P, Kneteman NM. Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validation. Hepatology. 2015, 62:158-65. 10.1002\/hep.27787","journal-title":"Hepatology"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v25.i11.1289","article-title":"Emerging role of 18F-fluorodeoxyglucose positron emission tomography for guiding management of hepatocellular carcinoma","volume":"25","author":"Lee SM","year":"2019","unstructured":"Lee SM, Kim HS, Lee S, Lee JW. Emerging role of 18F-fluorodeoxyglucose positron emission tomography for guiding management of hepatocellular carcinoma. World J Gastroenterol. 2019, 25:1289-306. 10.3748\/wjg.v25.i11.1289","journal-title":"World J Gastroenterol"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.11.017","article-title":"Advances in resection and transplantation for hepatocellular carcinoma","volume":"72","author":"Vibert E","year":"2020","unstructured":"Vibert E, Schwartz M, Olthoff KM. Advances in resection and transplantation for hepatocellular carcinoma. J Hepatol. 2020, 72:262-76. 10.1016\/j.jhep.2019.11.017","journal-title":"J Hepatol"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.09.025","article-title":"Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma","volume":"154","author":"Mazzaferro V","year":"2018","unstructured":"Mazzaferro V, Sposito C, Zhou J, et al.. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma. Gastroenterology. 2018, 154:128-39. 10.1053\/j.gastro.2017.09.025","journal-title":"Gastroenterology"},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0073-4","article-title":"Molecular therapies and precision medicine for hepatocellular carcinoma","volume":"15","author":"Llovet JM","year":"2018","unstructured":"Llovet JM, Montal R, Sia D, Finn RS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018, 15:599-616. 10.1038\/s41571-018-0073-4","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/74102-hepatocellular-carcinoma-in-2021-an-exhaustive-update","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:36:13Z","timestamp":1707507373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/74102-hepatocellular-carcinoma-in-2021-an-exhaustive-update"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,5]]},"references-count":133,"URL":"https:\/\/doi.org\/10.7759\/cureus.19274","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11,5]]}}}